Method for differentiating mesenchymal stem cells from totipotent stem cells
A method using microgravity-induced three-dimensional culture and adherent polymer coating efficiently differentiates totipotent stem cells into mesenchymal stem cells with high yield and therapeutic potential for regenerative medicine.
Patent Information
- Application Number
- JP2022566733
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-05-07
- Filing Date
- 2021-05-07
- Publication Date
- 2024-11-21
- Estimated Expiration
- 2041-05-07
AI Technical Summary
Existing methods for obtaining mesenchymal stem cells are limited by the availability of adult tissue sources and invasive procedures, posing risks to donors, and there is a need for a more efficient method to produce clinically useful mesenchymal stem cells.
A method involving three-dimensional suspension culture of totipotent stem cells under microgravity conditions followed by adherent culture on a polymer-coated surface to form spheroids, which are then differentiated into mesenchymal stem cells, enhancing yield and proliferation.
The method produces mesenchymal stem cells with high yield and excellent proliferation rates, exhibiting superior tissue regeneration and immunomodulatory activities, suitable for treating bone, cartilage, inflammatory, and autoimmune diseases.
Smart Images

Figure 0007587867000002 
Figure 0007587867000003 
Figure 0007587867000004
Abstract
Description
[Technical field]
[0001] The present invention relates to a method for differentiating mesenchymal stem cells from totipotent stem cells by sequentially performing three-dimensional culture and adherent culture under microgravity. [Background technology]
[0002] Human pluripotent stem cells (hPSCs), including human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs), can proliferate indefinitely while maintaining the ability to differentiate into various types of somatic cells. These cells are highly valued in cell therapy and regenerative medicine because they provide an unlimited source of cells, and research is being actively conducted into various differentiation induction methods for specifically differentiating cells with a morphology suitable for the tissue to be regenerated, methods for isolating differentiated cells, and methods for removing undifferentiated cells.
[0003] Meanwhile, mesenchymal stem cells (MSCs), which were first identified in bone marrow, are totipotent cells with great potential in regenerative medicine. Mesenchymal stem cells can differentiate into various types of mesenchymal lineages, such as bone cells, chondrocytes, adipocytes, muscle cells, and fibroblasts, and can be used as a composition for treating various autoimmune and inflammatory diseases, such as transplantation promoters, fetal grafts, and host diseases, due to their immunomodulatory activity (Le Blanc K et al., Lancet, 363(9419):1439-1441, 2004; El-Badri NS et al., Exp Hematol, 26 (2):110-116, 1998). Mesenchymal stem cells can be isolated from various human tissues, such as bone marrow, adipose tissue, umbilical cord blood, peripheral blood, neonatal tissue, and placenta, but there is a limit to the number of mesenchymal stem cells that can be obtained from adult tissues, and isolating mesenchymal stem cells requires invasive procedures, which may pose unexpected risks to the donor. Therefore, the present inventors aimed to provide a new alternative for obtaining stem cells for therapy in regenerative medicine by developing a method for efficiently obtaining therapeutically effective amounts of mesenchymal stem cells from totipotent stem cells.
[0004] Numerous articles and patent documents are referenced and cited throughout this specification, the disclosures of which are incorporated herein by reference in their entireties to more clearly describe the state of the art to which this invention pertains and the content of the present invention.
[0005]
[0006] [Prior art documents] [Patent documents]
[0007] Patent Document 1) Patent Document 1 Korean Application No. 10-2011-0107237 Summary of the Invention [Problem to be solved by the invention]
[0008] The present inventors have made extensive research efforts to develop a method for efficiently differentiating mesenchymal stem cells with excellent clinical utility from all-potential stem cells. As a result, they have found that when embryoid bodies obtained by suspension culture of all-potential stem cells are cultured in a three-dimensional culture vessel under artificially induced zero or microgravity to form spheroids, and then the spheroids are cultured in a culture vessel coated with an adhesive polymer as adherent culture, mesenchymal stem cells with excellent inherent pharmacological effects such as tissue regeneration and immune regulation activity and excellent proliferation rate can be obtained in high yields, thereby completing the present invention.
[0009] It is therefore an object of the present invention to provide a method for producing mesenchymal stem cells from pluripotent stem cells.
[0010] Another object of the present invention is to provide mesenchymal stem cells prepared by the method of the present invention and a composition for treating bone diseases, cartilage diseases, inflammatory diseases, or autoimmune diseases, comprising the mesenchymal stem cells as an active ingredient.
[0011] Further objects and advantages of the present invention will become more apparent from the following detailed description of the invention, the claims and the drawings. [Means for solving the problem]
[0012] According to one aspect of the present invention, there is provided a method for producing mesenchymal stem cells from totipotent stem cells, comprising the steps of:
[0013] (a) culturing total stem cells isolated from a subject to form embryoid bodies (EBs);
[0014] (b) culturing the embryoid bodies in a three-dimensional manner in a bioreactor under microgravity to form spheroids; and
[0015] (c) A step of adhering and culturing the spheroids in a culture vessel having a culture surface coated with an adhesive polymer, thereby differentiating the spheroids into mesenchymal stem cells.
[0016] The present inventors have made extensive research efforts to develop a method for efficiently differentiating puripotent stem cells into mesenchymal stem cells with excellent clinical utility. As a result, they have found that when embryoid bodies obtained by suspension culture of puripotent stem cells are cultured in a three-dimensional culture vessel under artificially induced zero or microgravity to form spheroids, and then these are cultured in a culture vessel coated with an adhesive polymer as adherent culture, mesenchymal stem cells with excellent proliferation rates and superior inherent pharmacological effects such as tissue regeneration and immune regulation activity can be obtained in high yields.
[0017] As used herein, the term "stem cell" refers to an undifferentiated cell at a stage before it differentiates into each cell that constitutes a tissue, and is a collective term for cells that have the ability to differentiate into a specific cell under a specific differentiation stimulus (environment). Stem cells differ from differentiated cells whose cell division has stopped, in that they can produce identical cells through cell division (self-renewal), and when a differentiation stimulus is applied, they can differentiate into various cells depending on the nature of the stimulus, and are characterized by their differentiation plasticity.
[0018] The stem cells used in the present invention can be any cells that have the characteristics of stem cells, i.e., undifferentiation, unlimited proliferation, and the ability to differentiate into specific cells, and can be induced to differentiate into the tissue to be regenerated, without any restrictions.
[0019] According to a specific embodiment, the stem cells used in the present invention are mesenchymal stem cells.
[0020] The term "mesenchymal stem cells" as used herein refers to stem cells with multipotency that can differentiate into adipocytes, bone cells, chondrocytes, muscle cells, nerve cells, and cardiomyocytes. Mesenchymal stem cells can be identified by their spiral morphology and expression of basic cell surface markers CD73(+), CD105(+), CD34(-), and CD45(-), and have the ability to regulate immune responses in addition to their multipotency.
[0021] The term "pluripotent stem cell" as used herein refers to a stem cell that is in a more advanced developmental state than a fertilized egg and can differentiate into all of the cells constituting the endoderm, mesenchyme, and ectoderm. According to a specific embodiment of the present invention, the totipotent stem cell used in the present invention is an embryonic stem cell (ESC), an embryonic germ cell, an embryonic carcinoma cell, or an induced pluripotent stem cell (iPSC), more specifically, an embryonic stem cell or an induced pluripotent stem cell, and most specifically, an induced pluripotent stem cell.
[0022] The term "induced pluripotent stem cell" as used herein refers to a type of pluripotent stem cell artificially derived by inserting specific genes associated with an undifferentiated or pluripotent phenotype into a non-pluripotent cell (e.g., somatic cell). Induced pluripotent stem cells are considered in the art to have the same phenotype, physiological characteristics, and developmental properties as naturally occurring pluripotent stem cells such as embryonic stem cells, in terms of expression of stem cell genes and proteins, chromosomal methylation, doubling time, formation of embryoid bodies, formation of teratomas, formation of viable chimeras, hybridization, and differentiation.
[0023] As used herein, the term "stem cell differentiation" includes not only the case where an undifferentiated stem cell is induced to completely differentiate into a specific cell, but also the formation of precursor cells that are formed at an intermediate stage before a stem cell is completely differentiated into a specific cell.
[0024] The cell culture medium used in each step of the present invention is a mixture for in vitro cell growth and proliferation, containing essential elements for cell growth and proliferation, such as sugars, amino acids, various nutrients, minerals, etc. Further components that may be included in the cell culture medium include, for example, glycerin, L-alanine, L-arginine hydrochloride, L-cysteine hydrochloride-monohydrate, L-glutamine, L-histidine hydrochloride-monohydrate, L-lysine hydrochloride, L-methionine, L-proline, L-serine, L-threonine, L-valine, L-asparagine-monohydrate, L-aspartic acid, L-cystine 2HCl, L-glutamic acid, L-isoleucine, L-leucine, L-phenylalanine, L-tryptophan, L-tyrosine disodium salt dihydrate, i-inositol, thiamine hydrochloride, niacinamide, pyridoxine hydrochloride, biotin, calcium D-pantothenate, folic acid, riboflavin, vitamin B 12 , sodium chloride (NaCl), sodium bicarbonate (NaHCO3), potassium chloride (KCl), calcium chloride (CaCl2), sodium dihydrogen phosphate monohydrate (NaH2PO4-H2O), copper sulfate pentahydrate (CuSO4-5H2O), ferric sulfate heptahydrate (FeSO4-7H2O), magnesium chloride (anhydrous), magnesium sulfate (MgSO4), disodium hydrogen phosphate (Na2HPO4), zinc sulfate heptahydrate (ZnSO4-7H2O), D-glucose (dextrose), sodium pyruvate, sodium hypoxanthine, linolenic acid, lipoic acid, putrescine diHCl, and thymidine.
[0025] The cell culture medium according to the present invention can be artificially produced and used, or can be purchased and used as a commercially available medium. Examples of commercially available culture media include, but are not limited to, IMDM (Iscove's Modified Dulbecco's Medium), α-MEM (Alpha Modification of Eagle's Medium), F12 (Nutrient Mixture F-12), and DMEM / F12 (Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12).
[0026] According to a specific embodiment of the present invention, the step (a) is carried out by three-dimensionally culturing the all-potential stem cells in a multi-well culture vessel.
[0027] In the present specification, the term "three-dimensional culture" is a concept opposite to two-dimensional culture, and refers to culturing the cells to be cultured in a floating state in a culture solution without fixing them to a substrate or the like. Therefore, the term "three-dimensional culture" is used as the same meaning as "suspension culture". Since adhesion-dependent stem cells undergo cell aggregation during suspension culture, and cells that are not included in such aggregation and float alone induce apoptosis and die, cells must form an environment that suits their adhesion characteristics. According to the present invention, by culturing totipotent stem cells in a suspension culture in a multi-well having multiple wells, totipotent stem cell aggregates with a diameter according to the well size, i.e., embryoid bodies (EBs) are formed in proportion to the number of wells. Therefore, in step (a) of the present invention, standardized embryoid bodies having the same size and shape can be obtained in large quantities.
[0028] More specifically, the multi-well culture vessel is a microwell plate having a size of 350 μm×350 μm to 450 μm×450 μm per well.
[0029] According to a specific embodiment of the present invention, the suspension culture is 0.5×10 per well in the multi-well culture vessel. 5 ~1.5×10 5 This is done by dividing 0.7 × 10 cells into subpopulations. 5 ~1.3×10 5 cells, most specifically, 0.9 × 10 5 ~1.1×10 5 The cells are divided into strains.
[0030] More specifically, the step (a) further comprises inducing cell aggregation during the suspension culture by centrifugation.
[0031] The term "cell aggregate" as used herein means that cells cultured in an environment that allows three-dimensional growth, such as suspension culture, rather than in a monolayer, self-aggregate to form a three-dimensional structure of cell aggregates. The cell aggregates obtained as a result of three-dimensional culture provide an environment similar to the in vivo tissue from which stem cells are derived, and may be spherical or non-spherical in shape depending on the size and number of self-assembled cells.
[0032] According to a specific embodiment of the present invention, the microgravity in step (b) is induced by a microgravity simulator which counteracts the gravity applied to the bioreactor by rotating the bioreactor.
[0033] As used herein, the term "microgravity" means that gravity is absent or exists only below measurable levels, or exists only to the extent that the biological and physiological effects of gravity are not observed, and specifically, is less than 1×10 6 It refers to an environment with a temperature of less than 1000 K. Thus, the term "microgravity" can also be expressed as "weightlessness."
[0034] The term "microgravity simulator" as used herein refers to a device that induces a microgravity environment by artificially canceling gravity in a normal gravity environment or an environment where significant gravity exists. Examples of such microgravity simulators include, but are not limited to, clinostats, RPMs (random positioning machines), and RWVs (rotating wall vessels), and any device that can cancel gravity for a specified time in the culture environment in the bioreactor of the present invention through the application of an appropriate external force can be used without limitation.
[0035] According to a specific embodiment of the present invention, the microgravity simulator of the present invention is a clinostat, which is a device that is connected to a culture vessel such as a bioreactor and rotates while continuously changing direction randomly or according to a specified (input) pattern, constantly changing its three-dimensional posture to cause continuous variation in the direction of gravity, thereby counteracting gravity.
[0036]
[0037] According to a specific embodiment of the present invention, the step (b) is performed by culturing the microgravity simulator for 3 to 8 days while rotating the simulator at 40 to 80 rpm, more specifically, culturing the microgravity simulator for 4 to 7 days, and most specifically, culturing the microgravity simulator for 5 days.
[0038] More specifically, step (b) is performed by rotating the microgravity simulator starting at 40-60 rpm and increasing by 5 rpm each day, most specifically, starting at 50 rpm and increasing by 5 rpm each day for 5 days.
[0039] The term "bioreactor" as used herein means a culture device or system for biological samples that includes a culture space for forming a culture environment having biological activity and a series of mechanical devices that operate in conjunction therewith.
[0040] According to the present invention, in step (b) of the method of the present invention, the embryoid bodies generated in step (a) are three-dimensionally cultured in a bioreactor under microgravity to form spheroids. A spheroid is a spherical cell aggregate, but does not necessarily have to be a perfect sphere geometrically.
[0041]
[0042] According to the present invention, the method of the present invention comprises two steps of 3D suspension culture in steps (a) and (b), and then the spheroids formed through the three-dimensional suspension culture are cultured in an adhesive polymer-coated culture vessel to differentiate into mesenchymal stem cells.
[0043] The term "polymer" as used herein refers to a synthetic or natural polymeric compound consisting of successively linked monomers of the same or different types. Thus, polymers include homopolymers (polymers in which one type of monomer is polymerized) and hybrid polymers made by polymerization of at least two different monomers, which in turn include both copolymers (polymers made from two different monomers) and polymers made from more than two different monomers.
[0044] The term "adhesive polymer" as used herein means a natural or artificial polymer that forms a bridge via a covalent or non-covalent bond between a culture surface and cells or aggregates thereof (e.g., spheroids), allowing the cells or aggregates thereof to remain attached to the bottom or side of the culture vessel without escaping and allowing the culture to proceed.
[0045] According to a specific embodiment of the present invention, the adhesive polymer is selected from the group consisting of hyaluronic acid, alginate, heparin, fucoidan, cellulose, dextran, chitosan, albumin, fibrin, collagen, and gelatin. More specifically, the adhesive polymer is gelatin.
[0046]
[0047] According to another aspect of the invention, the invention provides mesenchymal stem cells produced by the method of the invention.
[0048] In yet another aspect, the present invention provides a composition for treating bone or cartilage diseases, comprising the mesenchymal stem cells of the present invention as an active ingredient.
[0049] The term "treatment" as used herein means (a) suppression of the onset of a disease, illness or symptom, (b) alleviation of a disease, illness or symptom, or (c) elimination of a disease, illness or symptom. Mesenchymal stem cells differentiated by the method of the present invention are efficiently differentiated into bone and cartilage, and serve to suppress the onset, eliminate or alleviate symptoms of various bone or cartilage diseases caused by irreversible quantitative loss of bone or cartilage tissue. Thus, the composition of the present invention can be a composition for treating these diseases by itself, or can be administered in combination with other pharmacological ingredients and applied as a therapeutic adjunct to the above diseases. Thus, the term "treatment" or "therapeutic agent" as used herein includes the meaning of "therapeutic adjunct" or "therapeutic adjunct".
[0050] As used herein, the term "administration" refers to administering a therapeutically effective amount of the composition of the present invention directly to a subject, so that the same amount is formed in the subject's body, and has the same meaning as "implantation" or "injection." As used herein, the term "implantation" refers to the process of delivering viable cells or an artificial support that receives them from a donor to a recipient, with the goal of maintaining the functional integrity of the transplanted cells in the recipient.
[0051] The term "therapeutically effective amount" in the present invention means the content of the composition contained in an amount sufficient to provide a therapeutic or prophylactic effect to an individual to whom the composition of the present invention is to be administered, and includes a "prophylactically effective amount."
[0052] The term "subject" as used herein includes, without limitation, a human, a mouse, a rat, a guinea pig, a dog, a cat, a horse, a cow, a pig, a monkey, a chimpanzee, a baboon, or a rhesus monkey. Specifically, the subject of the present invention is a human.
[0053] The term "bone disease" as used herein includes all diseases that are or may be accompanied by damage to bone tissue caused by various causes, including trauma, bone fracture, bone metastasis of cancer cells, and excessive activity of osteoclasts. Specifically, bone diseases that can be prevented or treated with the composition of the present invention include, but are not limited to, osteoporosis, osteogenesis imperfecta, periodontal disease, bone fracture, metabolic osteitis, osteitis fibrosa, amorphic bone disease, osteomalacia, rickets, hypercalcemia, multiple myeloma, and Pazet's disease.
[0054] The term "cartilage disease" as used herein refers to a disease in which cartilage tissue loses its original function due to death of chondrocytes or quantitative loss of cartilage tissue, such as degenerative arthritis.
[0055] According to another aspect of the present invention, there is provided a composition for treating an inflammatory disease or an autoimmune disease, comprising the mesenchymal stem cell of the present invention as an active ingredient.
[0056] According to the present invention, it has been confirmed that mesenchymal stem cells differentiated by the method of the present invention have excellent anti-inflammatory and immunomodulatory activities by significantly suppressing inflammatory factors in cells in which inflammation is induced by LPS.
[0057] According to a specific embodiment of the present invention, examples of autoimmune or inflammatory diseases that may be prevented or treated by the compositions of the present invention include, but are not limited to, rheumatoid arthritis, reactive arthritis, type 1 diabetes, type 2 diabetes, systemic lupus erythematosus, multiple sclerosis, idiopathic fibrosing alveolitis, polymyositis, dermatomyositis, localized dermatosclerosis, systemic dermatosclerosis, colitis, inflammatory bowel disease, Sjorgen's syndrome, Raynaud's phenomenon, Bechet's disease, Kawasaki's disease, primary biliary sclerosis, primary sclerosing cholangitis, ulcerative colitis, graft-versus-host disease (GVHD), and Crohn's disease.
[0058] When the composition of the present invention is prepared as a pharmaceutical composition, the pharmaceutical composition of the present invention includes a pharma- ceutical acceptable carrier. Furthermore, the pharmaceutical composition can be formulated into a unit-dose preparation suitable for administration to the patient's body according to a conventional method in the pharmaceutical field. Suitable dosage forms for this purpose include solutions or suspensions for parenteral administration, and ointments for topical administration. When formulating the composition of the present invention, commonly used diluents or excipients such as fillers, weighting agents, binders, wetting agents, disintegrants, and surfactants can be used in combination. The single dose of the composition can be about 1 μg to 50 mg per kg of body weight based on the total composition, and the dose of therapeutic stem cells is about 1 to 10 mg per day based on an adult. 8 , 10~10 5 , 10 2 ~10 3The dose may be one or more times a day. The dose may be divided into one or several times a day. However, the dose and number of doses may be determined in consideration of factors such as the severity of the disease, the route of administration, as well as the weight, age, and sex of the patient. Effect of the Invention
[0059] The features and advantages of the present invention can be summarized as follows:
[0060] (a) The present invention provides a method for preparing mesenchymal stem cells from pluripotent stem cells and mesenchymal stem cells prepared by said method.
[0061] (b) The present invention uses totipotent stem cells, particularly induced pluripotent stem cells (iPSCs), as starting cells and sequentially performs 3D suspension culture and adherent culture of the cell aggregates formed thereby, thereby making it possible to obtain mesenchymal stem cells with excellent inherent biological activity and excellent proliferation rate in high yields.
[0062] (c) The mesenchymal stem cells prepared by the method of the present invention exhibit high differentiation efficiency into bone and cartilage and have excellent inflammation suppressing activity, and therefore can be usefully used as a composition for treating bone diseases, cartilage diseases, or inflammation and autoimmune diseases. [Brief description of the drawings]
[0063] [Figure 1] FIG. 1 shows a schematic diagram summarizing the protocol of the present invention for differentiating MSCs from iPSCs.
[0064] [Diagram 2] FIG. 1 shows the morphology of embryoid bodies (EBs) formed on Aggrewell.
[0065] [Diagram 3]This shows the morphology of spheroids (top) formed using a microgravity biological incubator, BAM (Bio Array Matrix), and the results of staining with OCT4 and DAPI antibodies (bottom).
[0066] [Figure 4] This is a diagram showing the external appearance of spheroid-derived mesenchymal stem cells, which were confirmed to exhibit a spindle morphology after passaging (right side).
[0067] [Diagram 5] FIG. 5 shows the appearance of MSCs differentiated by the method of the present invention at each passage.
[0068] [Figure 6a] FIG. 6a shows a cumulative cell proliferation curve of mesenchymal stem cells differentiated by the method of the present invention, showing CPD (Cumulative Population Doubling) at each passage. [Figure 6b] FIG. 6b shows a cumulative cell proliferation curve of mesenchymal stem cells differentiated by the method of the present invention, showing the doubling time at each passage. [Figure 6c] FIG. 6c shows a cumulative cell proliferation curve of mesenchymal stem cells differentiated by the method of the present invention, showing the Log cell number at each passage.
[0069] [Figure 7] FIG. 1 shows the results of FACS analysis of cell surface marker expression in mesenchymal stem cells differentiated by the method of the present invention.
[0070] [Figure 8] FIG. 1 shows the results of confirming, by Alizarin Red S, Oil Red O and Alcian Blue staining, that mesenchymal stem cells differentiated by the method of the present invention are differentiated into fat, bone and cartilage.
[0071] [Figure 9]FIG. 1 shows the results of immunocytochemistry confirming that the method of the present invention caused induced pluripotent stem cells to lose totipotency and differentiate into cells expressing mesenchymal stem cell markers.
[0072] [Figure 10] FIG. 1 shows a schematic diagram of the experimental procedure for confirming the inflammation-suppressing effect of stem cells differentiated by the method of the present invention in inflammation-induced cells using LPS.
[0073] [Figure 11] FIG. 1 shows the results of confirming the expression of inflammatory markers by RT-PCR. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0074] The present invention will be described in more detail below with reference to examples. It will be obvious to those skilled in the art that these examples are merely intended to more specifically illustrate the present invention, and that the scope of the present invention is not limited to these examples according to the gist of the present invention.
[0075]
[0076] <Example>
[0077]
[0078] <Experimental Method>
[0079] Cultivation of single colonies
[0080] iPSCs were attached as single cells to a 96-well plate coated with Matrigel (354234, Corning, USA) and cultured in iPSC medium for 1 week to generate single colonies. Each colony obtained was subcultured in turn onto a 24-well dish coated with Matrigel, then onto a 6-well dish, and finally reached 1 × 10 5 When the cell numbers increased to about 100%, they were used for spheroid experiments (Figure 1).
[0081]
[0082] Generation of spheroids using the BAM system
[0083] iPSCs were plated in Aggrewell plates (34460, Stemcell, Canada) at 1 × 10 5 After seeding at about 1000 x g, the cells were centrifuged at 300 g for 5 minutes to aggregate, and then cultured in a 5% CO2 incubator for 24 hours to generate embryoid bodies (EBs). The EBs generated after 24 hours were carefully transferred to a bioreactor (Bioreactor, CelVivo, Denmark), which was then placed in a microgravity device, the BAM system (CelVivo, Denmark), and rotated for 5 days. The rotation started at 50 rpm and was increased by 5 rpm every day (Figure 1).
[0084]
[0085] Generation of iPSC-MSCs
[0086] Spheroids grown in the BAM system were transferred to 0.1% gelatin-coated 6-well culture dishes and cultured in DMEM / F12 supplemented with 10% FBS and 1% P / S, with the medium replaced every 2-3 days. When the cells emerged from the spheroids attached to the coated bottom and reached 70-80% confluence, they were passaged using Tryple. The first passage was called P0, and cells were passaged until the cell shape became homogenous.
[0087]
[0088] Identification of pluripotent and mesenchymal stem cells using immunocytochemistry (ICC) staining
[0089] The spheroids generated at the iPSC stage were partially removed from the bioreactor and fixed with 4% paraformaldehyde (PFA). The iPSC-MSCs generated from the iPSC spheroids were plated at 1 × 10 5After seeding at a concentration of 1000 mM NaCl, the spheroids were fixed in 4% PFA at 60-70% confluence. The fixed spheroids and iPSC-MSCs were washed with DPBS three times for 5 minutes, and then the surface was permeabilized with 0.3% Triton X-100 to allow good antibody penetration. After that, they were washed with DPBS three times for 5 minutes. The washed spheroids were cultured at room temperature for 1 hour in 3% BSA / PBS for blocking. After 1 hour, the 3% BSA / PSB was removed, and the primary antibodies (1:200) Anti-OCT4, Anti-SSEA4, and Anti-PDGFRβ were added and reacted in a refrigerator for 12 hours. After 12 hours, the spheroids were taken out to room temperature and washed with DPBS three times for 5 minutes each. After washing, the spheroids were cultured at room temperature for 1 hour with goat anti-mouse 488 as the secondary antibody (1:200). After 1 hour, the secondary antibody was removed, and the specimens were stained with DAPI or Topro3 for 20 minutes to stain the nuclei, and then washed three times with DPBS for 5 minutes each. The washed specimens were then used with Antifade Mounting Medium (H-1000, VECTOR LABORATORY, UK) to prevent loss of fluorescence.
[0090]
[0091] iPSC-MSC passaging and cell proliferation curve
[0092] Cell morphology was recorded from the passage where the shape of iPSC-MSC became homogenous, and the cell number was calculated to plot the proliferation curve. From P5, iPSC-MSC were cultured at 2 × 10 5After seeding with the number of cells, the cells were cultured for 5 days, and the medium was changed once every 5 days. Cell proliferation was shown by three proliferation curves. First, the cell number of the cell growth rate (CPD: Cumulative Population Doubling level) was calculated as "CPD = log (cell number after / initial cell number) / log (2)". Next, the doubling time, which is the time it takes for the cells to double, was calculated as "Doubling Time = number of days of culture × log (2) / (log (cell number after) - log (initial cell number))". Then, the cell number, which is the value obtained by calculating the cell number at the time of passage and taking the log, was calculated as "cell number = log (cell number)". The calculated values are shown in a line graph, and AD-MSCs and hWJ-MSCs were used as controls.
[0093]
[0094] Immunophenotyping using flow cytometry (FACS) analysis
[0095] TrypLE cells in culture TM The cells were separated using Express (10624013, Gibco, USA), centrifuged at 1,500 rpm for 5 minutes, the supernatant was removed, and the cells were suspended in FACS buffer (D-PBS containing 2% FBS), and then subjected to primary reaction with mouse anti-CD34, mouse anti-CD45, mouse anti-CD73, and sheep anti-CD90. These primary antibodies were diluted 1:500, and 200 μl each was added to the cells, and then cultured at 4 ° C for 30 minutes. Next, after washing with D-PBS, the cells were centrifuged at 1,500 rpm for 5 minutes, the supernatant was removed, and 200 μl each of the secondary antibodies rabbit anti-mouse 488 or donkey anti-sheep PE diluted 1:500 was added and cultured at 4 ° C for 20 minutes. The stained cells were then suspended in 500 μL of FACS buffer and subjected to flow cytometry using a flow cytometer (FACS Calibur; Becton Dickinson, Heidelberg, Germany) and analyzed using a Cell Quest pro swartor.
[0096]
[0097] Induction of bone formation, fat and cartilage differentiation
[0098] For induction of triple lineage differentiation, cells were cultured in 24-well plates at 2 × 10 4 Cells were allowed to attach per well and differentiation was initiated when they reached 80% confluency.
[0099] For osteogenic differentiation, Dulbecco's modified Eagle's medium (DMEM)-low glucose (Invitrogen, CA, USA) was supplemented with 10% FBS, 1% penicillin / streptomycin (P / S), 100 nM dexamethasone (Sigma-Aldrich, MO, USA), 50 μg / ml ascorbate-2-phosphate (Sigma-Aldrich, MO, USA), and 10 mM β-glycerophosphate (Sigma-Aldrich, MO, USA). The differentiation medium was changed every 2 days for 2 weeks. At the end of differentiation, cells were fixed with 4% PFA for 15 min and then washed with sterile water. Differentiation verification was performed by staining for accumulated mineral calcium phosphate using Alizarin Red S staining method.
[0100] For adipogenesis, DMEM-high glucose was supplemented with 10% FBS, 1% P / S, 500 μM isobutylmethylxanthine, 1 μM dexamethasone, 100 μM indomethacin, and 10 μg / ml insulin. Differentiation medium was changed every 3 days for 2 weeks. At the end of differentiation, cells were fixed with 4% PFA for 15 min, washed first with sterile water, and then washed a second time with 60% isopropanol. Differentiation was verified by staining for intracellular lipid accumulation using 5% Oil Red O diluted in isopropanol (wt / vol).
[0101] For chondrocyte differentiation, DMEM-high glucose was supplemented with 2% FBS, 1% P / S, 50 μg / mL ascorbate-2-phosphate, 100 μg / mL sodium pyruvate, 1% insulin-transferrin-selenium (ITS, Gibco), 100 nM dexamethasone, 40 μg / mL L-proline, and 10 ng / mL TGF-β3 (Prospec, East Brunswick, NJ, USA). The differentiation medium was changed every 2 days for 2 weeks. At the end of differentiation, the cells were fixed with 4% PFA for 15 min and then washed with sterile water. To verify differentiation, the cells were stained with Alcian blue, which stains acidic mucopolysaccharides such as glycosaminoglycans.
[0102]
[0103] Anti-inflammatory cell model
[0104] To evaluate the anti-inflammatory ability of the iPSC-MSC of the present invention, Raw 264.7 cells, which are macrophages used in an inflammatory cell model, were used. Raw 264.7 cells were cultured in α-MEM (Minimum Essential Medium) medium containing 10% FBS and 1% P / S. First, iPSC-MSC were cultured in a culture vessel for 48 hours, and then the conditioned medium was collected, filtered using a 0.20 μm syringe filter, and stored in a refrigerator at 4°C.
[0105] Raw 264.7 cells, 3.75 x 10 per well 5 The cells were seeded in 6-well culture dishes at 100°C for 12 hours. After 12 hours, when the cells had attached, the conditioned medium was replaced with the prepared medium. After 12 hours, all groups, including the conditioned medium group, except for the control group, were treated with 200ng / ml LPS (lipopolysaccharide, Sigma, USA) as shown in Figure 10. As a positive control group, LPS and DEX (Dexamathasone, Peprotech, USA) were treated at 1μM. After 7 hours, images were recorded and total RNA was isolated, followed by RT-PCR using IL-6, an inflammation marker.
[0106]
[0107] Total RNA isolation, RT-PCR
[0108] Total RNA was extracted from Raw264.7 cells using Labo Pass Kit, TRIzol (Cosmogenetech, Seoul, Korea) according to the manufacturer's manual. The concentration of total RNA was measured with a Nanodrop (ND1000) spectrophotometer (Nanodrop Technologies Inc., Wilmington DE, USA). cDNA was synthesized using 2 μg of total RNA and M-MLV reverse transcriptase (Promega) according to the manufacturer's manual. After completion of the RT-PCR reaction, it was analyzed on a 2% agarose gel. The sequences of the primers used are listed in Table 1.
[0109] [Table 1]
[0110] Experimental Results
[0111] Generation of spheroids using the BAM system
[0112] We confirmed that iPSCs plated on Aggrewell plates formed round EBs with uniform shape and size after 24 hours (Figure 2).
[0113]
[0114] Confirmation of pluripotent cells in spheroids by immunocytochemical staining
[0115] When the spheroids were stained with OCT4, a pluripotency marker, they were stained green, and when they were stained with DAPI, which stains the nucleus, the nucleus was stained green and blue specifically. It was found that OCT4 is expressed in the nucleus, and that the iPSC-derived spheroids maintained their pluripotency (Figure 3).
[0116]
[0117] Generation of iPSC-MSCs
[0118] In a culture dish coated with 0.1% gelatin, spheroids (black arrows) were observed to adhere to the bottom, and cells protruding from the bottom (white arrows) were observed. Over time, the number of protruding cells increased, and the cells were passaged at 70-80% confluence. As the passage proceeded, the shape of the cells became spindle-shaped (white dashed arrow) and homogenized (Figure 4).
[0119]
[0120] iPSC-MSC passaging and cell proliferation curve
[0121] iPSC-MSC cells showed spindle morphology from P5 and could be passaged up to P13 (Figure 5). The cells were then stored in LN2 using a storage solution. The cell proliferation curves were compared with those of the control groups, hWJ-MSC and AD-MSC. As a result, the cell number of AD-MSC increased up to P9 and then decreased, while the cell proliferation of hWJ-MSC was steady even at P13. The CPD and cumulative cell number of iPSC-MSC were much higher than those of the control group, and the doubling time was also faster than that of the control group (Figure 6).
[0122]
[0123] Immunophenotyping using flow cytometry (FACS)
[0124]
[0125] *FACS analysis confirmed that iPSC-MSCs were positive for anti-CD73 and anti-CD90 and negative for anti-CD34 and anti-CD45 compared to the control AD-MSCs (Figure 7), demonstrating that the iPSC-MSCs generated through the BAM system have distinct characteristics of mesenchymal stem cells.
[0126]
[0127] Induction of bone formation, fat and cartilage differentiation
[0128] We performed bone formation, fat and cartilage differentiation experiments using AD-MSCs and iPSC-MSCs. After 2 weeks of differentiation, we stained them with Alizarin Red S, Oil Red O and Alcian Blue, respectively, and confirmed that iPSC-MSCs were also differentiated into bone, fat and cartilage, similar to the AD-MSCs used as a control. In particular, we observed that bone formation was efficient (Figure 8).
[0129]
[0130] Identification of mesenchymal stem cells in iPSC-MSCs by immunocytochemical staining
[0131] iPSC-MSC cells were subjected to ICC using the pluripotency markers OCT4 and SSEA4 and the mesenchymal stem cell marker PDGFRβ. In iPSC-MSCs, there were few green stained cells for the green OCT4 and SSEA4 markers, but there were many green stained cells for the green PDFGRβ marker. This indicates that iPSC-MSCs have lost their full differentiation potential and have been converted into mesenchymal stem cells.
[0132]
[0133] Inflammatory cell model
[0134] In the inflammation experiment, round cells were observed in the group that was not treated with LPS, and large multinucleated cells were observed in the cells that were treated with LPS to induce inflammation. On the other hand, no multinucleated cells were observed in the positive control group that was treated with LPS and DEX, and no large multinucleated cells were observed in the group that was treated with iPSC-MSC conditioned medium. When IL-6 expression was examined by RT-PCR, it was found to be high at 98% in the LPS-treated group, low at 14% in the LPS + DEX-treated group, and 65% in the iPSC-MSC conditioned medium-treated group. Therefore, it was found that the group that was treated with iPSC-MSC conditioned medium had a lower level of IL-6 expression than LPS (Figure 11).
[0135]
[0136] As described above, the specific parts of the present invention have been described in detail. It is obvious to those skilled in the art that such specific techniques are merely preferred embodiments and do not limit the scope of the present invention. Therefore, it is said that the substantial scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. A method for producing mesenchymal stem cells from pluripotent stem cells, comprising the steps of: (a) forming an embryoid body (EB) by three-dimensionally culturing a cell population of 0.5×10 5 to 1.5×10 5 pluripotent stem cells isolated from a subject for one day in a multi-well culture vessel having a size of 350 μm×350 μm to 450 μm×450 μm per well; (b) three-dimensionally culturing the embryoid bodies in a bioreactor under microgravity for 3-8 days to form spheroids, the microgravity being induced by a microgravity simulator that rotates the bioreactor to counteract gravity applied to the bioreactor; and (c) culturing the spheroids in an adhesive culture vessel having a culture surface coated with an adhesive polymer, thereby differentiating the spheroids into mesenchymal stem cells.
2. The method according to claim 1, wherein the pluripotent stem cells are embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs).
3. The method of claim 1, wherein the pluripotent stem cells are induced pluripotent stem cells.
4. The method according to any one of claims 1 to 3, wherein the step (a) further comprises the step of inducing cell aggregation by centrifugation during the three-dimensional culture.
5. 5. The method according to claim 1, wherein the step (b) is carried out by culturing the microgravity simulator for 3 to 8 days while rotating the microgravity simulator at 40 to 80 rpm.
6. 6. The method of claim 5, wherein step (b) is performed by rotating the microgravity simulator starting at 40-60 rpm and increasing by 5 rpm each day.
7. The method according to any one of claims 1 to 6, wherein the adhesive polymer is selected from the group consisting of hyaluronic acid, alginate, heparin, fucoidan, cellulose, dextran, chitosan, albumin, fibrin, collagen and gelatin.
8. The method according to any one of claims 1 to 7, characterized in that the adhesive polymer is gelatin.
9. A mesenchymal stem cell produced by the method according to any one of claims 1 to 8.
10. A composition for treating bone or cartilage diseases, comprising the mesenchymal stem cells according to claim 9 as an active ingredient.
11. A composition for preventing or treating an inflammatory disease or an autoimmune disease, comprising the mesenchymal stem cell according to claim 9 as an active ingredient.
12. The inflammatory disease or autoimmune disease includes rheumatoid arthritis, reactive arthritis, type 1 diabetes, type 2 diabetes, systemic lupus erythematosus, multiple sclerosis, idiopathic fibrosing alveolitis, polymyositis, dermatomyositis, localized dermatosclerosis, systemic dermatosclerosis, colitis, inflammatory bowel disease, Sjögren's syndrome, Raynaud's phenomenon, Bechet's disease, Kawasaki's disease, primary biliary sclerosis, primary sclerosing cholangitis, ulcerative colitis, and the like. olitis), graft-versus-host disease (GVHD), or Crohn's disease.
Citation Information
Patent Citations
Method of dynamically culturing embryonic stem cells
US20110027887A1
Method of constructing artificial joint
WO2005011765A1
Method for culturing pluripotent stem cells
WO2016052657A1
Cell aggregation including olfactory neuron or precursor cell thereof, and method for producing same
WO2020039732A1
